Diabète de type 2 et proprotein convertase subtilisin/kexin type 9 : y-a-t-il un lien ?

Un analogue non archimédien d’un résultat de Haagerup et lien avec la propriété (T) renforcée

Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)

BACKGROUND Abnormalities in lipid and glucose metabolism are constantly observed in type 2 diabetes. However, these abnormalities can be ameliorated by polydatin. Considering the important role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in metabolic diseases, we explore the possible mechanism of polydatin on lipid and glucose metabolism through its effects on PCSK9. METHODS An i...

Caractéristiques de l'association diabète type 2 et hypertension artérielle chez le sujet âgé de 65 ans et plus

Introduction: L’HTA du diabétique âgé est particulière par sa fréquence et sa gravité. Cette association HTA-diabète type 2 (DT2) est particulièrement fréquente chez la personne âgée, et responsable d’une majoration du risque cardiovasculaire et d’une accélération de l’atteinte dégénérative du diabète. Méthodes: Etude descriptive, concernant 100 patients diabétiques de type 2 hypertendus âgés d...

Proprotein convertase subtilisin/kexin type 9 levels and aortic valve calcification: A prospective, cross sectional study

OBJECTIVE To investigate the possible association between plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) and the incidence and severity of calcific aortic valve disease (CAVD). METHODS This prospective, cross sectional study involved patients with and without (controls) aortic valve calcification diagnosed by transthoracic echocardiography and dual source computed tomography (DS...

Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia.

The aim of the present study was to investigate the relationship between circulating PCSK9 (proprotein convertase subtilisin kexin type 9) and FCHL (familial combined hyperlipidaemia) and, when positive, to determine the strength of its heritability. Plasma PCSK9 levels were measured in FCHL patients (n=45), NL (normolipidaemic) relatives (n=139) and their spouses (n=72). In addition, 11 FCHL p...